Cellectis SA has taken a pivotal step in moving forward a potential first allogeneic, or "off-the-shelf," chimeric antigen receptor T-cell (CAR-T) therapy with the initiation of a clinical trial in the US. The company announced the first patient has been dosed in a Phase I clinical study testing the investigational product, UCART123, in patients with acute myeloid leukemia June 27.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?